Trials / Unknown
UnknownNCT03475615
A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
A Randomized Study of the Effect of First-line Intraperitoneal Paclitaxel in Combination With SOX Versus SOX Alone in Gastric Cancer Patients With Malignant Ascites
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 215 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to compare the efficacy of intraperitoneal paclitaxel in combination with SOX, with SOX alone in the first-line treatment of gastric cancer with malignant ascites
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxaliplatin | 130mg/m2, d1, q3w |
| DRUG | Paclitaxel | 40mg/m2 ip，d1、8 ,q3w |
| DRUG | S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules) | 40mg/m2 Bid po，d1-14,q3w |
Timeline
- Start date
- 2018-03-16
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2018-03-23
- Last updated
- 2018-03-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03475615. Inclusion in this directory is not an endorsement.